市场和行业上，港股相对A股弹性更大，成长相对涨幅更高。 华夏基金也从"日历效应"维度分析，恒生科技每年一季度的表现普遍较好，当前下跌风险提前释放后， 给了岁末年初重新入场、布局2026年的契机。 港股成长风格相关ETF： 12月16日，离岸人民币兑美元汇率一度升至7.04，创2024年10月4日以来新高；在岸人民币兑美元汇率 盘中最高升至7.04，创2024年10月8日以来新高。 与人民币升值形成鲜明对比的是，近期港股市场连续调整，调整幅度也大于A股。综合研究机构观点， 外部流动性的压制或是港股调整的主要原因。 一方面，虽然美联储如期降息25bp，但提前开启扩表，美债收益率近期呈现上升迹象；另一方面，市场 担忧日本央行将于12月19日重启加息周期，配合大规模经济刺激计划，进一步推升日债收益率并引发资 本回流担忧。 不过，华泰证券此前指出：自汇改以来，人民币经历了9轮升值周期，期间股市大多上涨。 恒生科技指数ETF（513180.SH）跟踪恒生科技指数规模最大的ETF 恒生互联网ETF（513330.SH）持有人户数最多的港股类ETF 港股通科技ETF基金（159101.SZ）覆盖最广泛的港股科技细分行业，包含 ...

Market Performance Review - The Hong Kong stock market indices experienced a V-shaped recovery this week, initially declining before rebounding, with the Hang Seng Composite Index, Hang Seng Index, and Hang Seng Tech Index closing down by -0.45%, -0.42%, and -0.43% respectively [5][15] - Value stocks and large-cap stocks outperformed, while growth stocks weakened. The financial and information technology sectors were the only ones to see gains, increasing by 0.88% and 0.34% respectively [5][15] - The energy sector faced significant declines, dropping by 5.35% due to weak international oil prices and lowered profit expectations [15] Valuation Levels - As of the end of this week, the 5-year PE (TTM) valuation percentile for the Hang Seng Composite Index stands at 83.39%, indicating that the valuation level is close to one standard deviation above the 5-year average [5] Buyback Statistics - The buyback market saw increased activity this week, with 81 companies participating, up by 6 from the previous week. The total buyback amount reached 5.219 billion HKD, an increase of 198 million HKD from last week [27] - Tencent Holdings (0700.HK) led the buyback activity with a total of 3.178 billion HKD, followed by Xiaomi Group (1810.HK) with 699 million HKD [27] Macro Environment Tracking - The overall profitability of the Hong Kong stock market is heavily reliant on Chinese state-owned enterprises, with over 80% of profits coming from mainland China, indicating a strong correlation with the economic conditions in China [39][40] - Key economic indicators show that China's trade value for the first 11 months of the year reached 41.21 trillion CNY, a year-on-year increase of 3.6%, with exports growing by 6.2% and imports by 0.2% [39][40] - The Central Economic Work Conference emphasized the need for "practicing internal skills to cope with external challenges," highlighting a shift in focus towards quality and efficiency in economic growth [43] Sector Outlook - The report suggests a favorable outlook for sectors benefiting from policy support, including new energy, innovative pharmaceuticals, and AI technology. Additionally, low-valuation state-owned enterprises and local Hong Kong banks, telecommunications, and utility stocks are expected to perform well during the interest rate easing cycle [5][43]

12月16日，A股三大股指低开低走，深成指，创业板指分别失守13000点及3100点关口，截止午盘，沪 指跌1.22%报3820.85点，深成指跌1.88%报12866.09点，创业板指跌2.35%报3063.97点，科创50指数跌 2.02%报1292.3点；沪深两市半日成交额1.12万亿，全市场超4400只个股下跌。 盘面上，智能驾驶概念逆势拉升，浙江世宝、索菱股份等十余股涨停；数字货币概念走强，翠微股份、 航天信息涨停；零售概念反复活跃，百大集团4连板，红旗连锁、广百股份双双2连板；下跌方面，影视 院线概念集体大跌，博纳影业2连跌停；海南板块下挫，海南瑞泽跌超9%；光伏板块走低，东方日升跌 超10%，中利集团逼近跌停，中闽能源、阿特斯、上能电气、艾罗能源、阳光电源均跌超5%。 热门板块 零售概念反复活跃 零售概念反复活跃，百大集团4连板，红旗连锁、东百集团、广百股份、汇嘉时代跟涨。 消息面上，三部门近日联合印发《关于加强商务和金融协同 更大力度提振消费的通知》，提出精准施 策推动惠民生和促消费紧密结合，形成提振和扩大消费的更大工作合力。 乳业概念再度走强 乳业概念再度走强，皇氏集团一字涨停晋级2连板，欢 ...

Group 1 - The innovative drug concept stocks have declined again, with notable drops in share prices for several companies [1] - Innovent Biologics (09969.HK) fell by 5.09%, trading at HKD 12.86 [1] - CSPC Pharmaceutical Group (01093.HK) decreased by 3.99%, with shares priced at HKD 7.21 [1] - Sinopharm Group (01801.HK) saw a decline of 3.36%, with its stock at HKD 79 [1]

值得关注的是，A股创新药大牛股一品红（300723）昨日意外跌停，今早再跌超13%。该公司参股的美 国Arthrosi公司收到收购要约，交易总金额最高可达15亿美元。有分析称，一品红的交易可能改变了一 些市场预期。此前市场预期的这个标的是按现在的收购价进行BD，但现在是直接卖出。而此前，股价 上涨太多，并且反应的是BD，现在预期走弱，故而股价跌停。 创新药概念股再度走低，截至发稿，诺诚健华(09969)跌5.09%，报12.86港元；石药集团(01093)跌 3.99%，报7.21港元；信达生物(01801)跌3.36%，报79港元。 中邮证券指出，下半年以来，国内的BD出海交易虽有短暂真空，但仍在持续，Q4以来亦诞生了多个 MNC为合作方的交易。该行认为，海外MNC的购买行为系对国内创新药公司创新研发的实力的背书认 可。进一步看，该行认为系中国创新药产业链能力、管线数量和质量、研发效率在全球的强大竞争优势 催生出的结果，坚定看好长期的产业趋势。 ...

Group 1: Market Overview - The market showed weakness with the Shanghai Composite Index down 0.51%, Shenzhen Component down 0.58%, and ChiNext down 0.66% as of 9:38 AM on December 16 [1] - Retail concepts were active, with Baida Group achieving four consecutive trading limits, and other companies like Hongqi Chain and Dongbai Group also seeing gains [1] - The dairy industry saw a resurgence, with Huangshi Group hitting a trading limit and achieving two consecutive trading limits, while companies like Huanlejia and Sunshine Dairy also rose [1] Group 2: Institutional Perspectives - Everbright Securities anticipates a favorable cross-year market for A-shares due to new policy deployments, which are expected to support economic growth and attract capital inflows [2] - Huaxi Securities notes that recent meetings have supported market risk appetite, with expectations for increased trading activity and investment in growth sectors like domestic substitution and innovative pharmaceuticals [3] - Oriental Securities emphasizes the importance of core technology sectors that are trending upwards, while also noting the market's structural volatility as it approaches the end of the year [4]

Core Viewpoint - The recent data indicates a significant adjustment in the sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping 3.32% to a five-month low, while over 75 million yuan was invested in the fund, marking a continuous inflow of over 200 million yuan in the past six days [1][9]. Fund Performance - The latest share count for the Hong Kong Stock Connect Innovative Drug ETF (520880) reached 4.148 billion shares, a record high since its launch, with the fund size at 2.165 billion yuan, also at a historical peak [4][11]. Market Dynamics - The fund's recent inflow is attributed to its value proposition, as the underlying index has seen a 21.56% pullback since early September, suggesting a favorable time for medium to long-term investment in core innovative drug assets [3][13]. - The National Healthcare Security Administration emphasized the importance of promoting innovative drug insurance coverage, encouraging commercial health insurance to include more reasonable medical expenses outside the basic insurance catalog [3][13]. Sector Outlook - Despite recent fluctuations in sentiment, the outlook for the innovative drug industry remains positive, with expectations for increased global competitiveness, successful international expansion, and commercial profitability by Q1 2026 [3][13]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) is highlighted for its unique advantages, including a pure focus on innovative drug companies, a significant weight of over 72% in leading firms, and controlled risks through the reduction of illiquid stocks [5][6][13]. Index Composition - The top ten holdings in the ETF account for 72.57% of the total weight, showcasing the dominance of leading companies in the innovative drug sector [7][14].

Core Viewpoint - The biopharmaceutical sector is expected to experience significant performance divergence among its sub-sectors before the third quarter of 2025, with industry revenue and profit growth rates initially declining before rebounding, as the pressures from high baselines, centralized procurement, and anti-corruption measures have been largely absorbed [1] Group 1: Innovative Drugs - The commercial insurance innovation drug catalog is set to debut in 2025, which is anticipated to drive incremental payments for innovative drug products [2] - The domestic new drug development is accelerating, with lower costs and favorable macro policies, leading to a global leadership position in innovative drug development, contributing approximately one-third of the global innovative R&D pipeline by 2025 [2] - The overseas rights BD transactions are driving the revaluation of innovative drug assets, with a continuous increase in the proportion of Chinese innovative drug license-outs [2] Group 2: CXO and Life Sciences - The CXO market is witnessing improved supply-demand dynamics, with CDMO companies entering a high prosperity cycle due to strong demand for new molecules like ADCs and peptides [2] - The life sciences upstream sector is experiencing a comprehensive recovery in downstream demand, with listed companies actively pursuing mergers and acquisitions to expand [3] Group 3: AI in Healthcare - The "Artificial Intelligence+" policy is leading to widespread applications of AI in healthcare, with significant developments driven by companies like Deepseek [3] Group 4: High-end Medical Equipment - The high-end medical equipment sector is poised for growth due to domestic procurement recovery, import substitution, and accelerated international expansion [3] Group 5: Orthopedic Joint Consumables - The negative impact of centralized procurement is clearing, and the aging population is driving market expansion, with potential growth in surgical robotics [3] Group 6: Traditional Chinese Medicine - There are signs of operational improvement in traditional Chinese medicine, with factors like flu season and basic drug catalog adjustments potentially catalyzing a new market cycle [4]

12月15日，A股缩量下跌，日成交额跌破1.8万亿元。科技股回调拖累创业板指跌近2%，科创50跌逾2%。盘面分化，大消费、券商板块护盘。 受访人士表示，科技部分细分领域可能因前期估值偏高、竞争加剧等因素，在市场情绪波动时率先调整。短期看，A股仍走结构性行情；年末机构结 算需求或抑制交投，但政策对经济和新兴产业的支持预期仍在，将为市场提供支撑。 电子、通信等科技板块领跌 指数方面，沪指早盘低开翻红，午后跳水，收跌0.55%，报3867.92点；创业板指全天弱势，收跌1.77%；科创50低开低走，收跌2.22%；北证50午后加 速下行，跌幅逾1%；沪深300、上证50微跌。 量能同步萎缩，日成交额骤降3246亿元至1.79万亿元。杠杆资金方面，截至12月12日，沪深京两融余额微降至2.5万亿元。 盘面上，热门技术股大跌。AI眼镜、AI手机、AIPC、电子设备制造、消费电子设备、通信设备、机器人、英伟达概念均大跌。零售、农业等大消费 方向收红，非银金融继续抬头。 8只商贸零售个股收涨，红旗连锁、全新好、百大集团、浙江东日、东百集团、农产品、广百股份、美凯龙涨停。 | 代码 | 名称 | . | 涨幅% ↓ | 最新 ...

Group 1: Core Insights - The pharmaceutical industry is entering a clear upward cycle with significant growth opportunities in innovative drugs and the innovation chain, driven by supportive policies and a global expansion trend [3][10] - The Chinese innovative drug sector is increasingly favored by international capital, with a record high of 149 transactions in 2025, accounting for 11% of global transaction numbers and 29% of total transaction value [10][37] - The introduction of commercial health insurance into the medical insurance negotiation process in 2025 is expected to diversify the payment system for innovative drugs, enhancing their market accessibility [10][37] Group 2: Innovative Drugs - The upward policy cycle supports innovation, with the latest round of drug procurement entering a new phase of quality-price balance, as seen in the 11th batch of centralized procurement [10][30] - The global patent cliff from 2025 to 2037 is projected to create a gap exceeding $300 billion, prompting multinational corporations (MNCs) to pursue business development (BD) and acquisitions to fill this gap [10][45] - Chinese innovative drugs are positioned to capitalize on this trend, particularly in areas such as second-generation immune-oncology (IO) and next-generation antibody-drug conjugates (ADCs) [10][50] Group 3: Innovation Chain - The innovation chain, including Contract Development and Manufacturing Organizations (CDMO) and Contract Research Organizations (CRO), is benefiting from both domestic and international demand, with CDMO orders showing a positive growth trend [12][12] - The overseas biopharmaceutical investment environment is improving, with a notable increase in funding as interest rates decline, which is expected to enhance the overall industry cycle [12][12] - The life sciences service sector is witnessing a recovery, driven by increasing domestic research demand and improved conditions for innovative drug development [12][13] Group 4: Market Opportunities - The domestic market for innovative drugs is projected to grow significantly, with over 400 innovative drugs approved since 2020, indicating strong internal growth potential [62][66] - As innovative drug companies transition to profitability, there is a potential shift in valuation methods from P/Peak Sales to PE, attracting broader investment interest [66] - Key companies to watch include AiLisi, Yunding Xinyao, and Kangnuo Ya, which are expected to benefit from the commercialization of innovative products [66]